Effects of the Rheumabuddy4.1 app on patients with rheumatoid arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of the digital app Rheumabuddy4.1 on patients diagnosed with rheumatoid arthritis (RA). The study aims to empower patients by enhancing their understanding of the disease and improving treatment adherence through the use of electronically reported outcomes. By integrating this digital health technology into standard care, the trial seeks to provide timely support that can lead to better quality of life for RA patients. The trial will assess the app's effectiveness in bridging the gap between healthcare professionals and patients regarding disease management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

An individual must meet all of the following criteria to be enrolled in the study:

1. Diagnosed with RA according to the EULAR \& American College of Rheumatology
2. PGA level \>= 40mm
3. Age ≥ 18 years and \< 65 years
4. Motivated for the intervention
5. Willing and able to understand and participate in the study
6. DAS28-CRP ≤ 3.2.
7. Ability to use the RB4.1 app

Exclusion Criteria:

An individual will be excluded from the study if she meets any of the following criteria:

1. Dementia or other linguistic/cognitive/physical deficiency that prevents participation
2. Vision impairment that prevents the use of the devices and computer
3. Change in DMARD (within 8 weeks)
4. Chronic widespread pain (fibromyalgia) based on patient anamnesis/medical record.
5. Acute infections based on patient anamnesis/medical record.
6. Severe asthma based on patient anamnesis/medical record.
7. Severe COPD based on patient anamnesis/medical record.
8. Instable heart disease based on patient anamnesis/medical record.
9. Intensive physiotherapy outside standard care based on patient anamnesis/medical record.
10. Electrostimulation based on patient anamnesis/medical record.
11. Motivation training based on patient anamnesis/medical record.
12. Smoking based on patient anamnesis/medical record.
13. Fever based on patient anamnesis/medical record.
14. If pain/fatigue are considered a side effect judged by the treating physician.
15. Other autoimmune diseases based on patient anamnesis/medical journal.
16. Mental diseases based on patient anamnesis/medical record.
17. All other non-pharmacological therapies that may impact the course of RA judged by the treating physician.
18. Any comorbid condition, that in the opinion of the investigator would interfere with the conduction of the trial or the interpretation of the study outcome.
19. Previous use of health apps related to the RA disease.

Where it's running

• The Parker Institute, Bispebjerg and Frederiksberg Hospital
  Frederiksberg, Copenhagen F, Denmark Recruiting

Study contacts

• Principal investigator: Henning Bliddal — The Parker Institute, Bispebjerg and Frederiksberg Hospital
• Study coordinator: Tanja Schjødt Jørgensen
• Email: tanja.schjoedt.joergensen@regionh.dk
• Phone: +4538164173

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• IV sarilumab for adults with rheumatoid arthritis

  This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.

  Recruiting at 12 sites Phase 1/2 Sanofi · Centennial, Colorado and 11 other locations · NCT07704580

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.